You are here: Industry Insights > Ibrance

News List

Pfizer files patent infringement petition in US court against Aurobindo, Dr Reddy’s expresspharma
November 19, 2020
Alleges that these Indian pharma companies were planning separately to come out with generic versions of its cancer drug Ibrance (palbociclib) before the expiration of its patent.
Pfizer’s Ibrance flunks early breast cancer trial pharmatimes
October 14, 2020
Pfizer’s oral CDK4/6 inhibitor Ibrance has failed to meet the primary endpoint of improved invasive disease-free survival (iDFS) in early breast cancer, nixing its chances in the adjuvant setting.
IBRANCE (palbociclib) fails trial for early breast cancer treatment expresspharma
October 10, 2020
No unexpected safety signals were observed and it did not meet improved invasive disease-free survival in women with HR+, HER2- early breast cancer in the PENELOPE-B trial.
Pfizer's Ibrance 'unlikely' to hit key early breast cancer goal pharmatimes
June 02, 2020
Pfizer's bid to develop Ibrance (palbociclib) for a certain form of early breast cancer has hit a critical setback after an early analysis of data concluded that it the drug was unlikely to hit its primary goal.
FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer drugs
April 17, 2019
FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer.
FDA approves Pfizer's Ibrance for advanced male breast cancer pharmafile
April 11, 2019
FDA approves Pfizer's Ibrance for advanced male breast cancer.
Pfizer's Innovative drug IBRANCE gets China approval biospectrumasia
August 10, 2018
World's First Kinase 4/6 (CDK 4/6) Inhibitor and Only Innovative Breakthrough Therapy for Advanced Breast Cancer in China over Past Ten Years
A slowing market—not new rivals—is hurting Pfizer's star cancer drug Ibrance, executives say pfizer
August 02, 2018
Pfizer breast-cancer fighter Ibrance posted a rare sales miss Tuesday, but it wasn't because new rivals are stealing its share.
In rare slip, Pfizer steamroller Ibrance fails to show it helps patients live longer biospectrumasia
June 26, 2018
More than two years ago, Pfizer’s Ibrance won an FDA nod to treat some breast cancer patients whose disease had progressed after endocrine therapy. But new study results suggest the drug may not actually help patients live longer.
Alliance Foundation Opens Trial Investigating Palbociclib in HR+, HER2+ MBC pharmaceutical-technology
August 23, 2017
The Alliance Foundation Trials (AFT), in conjunction with Pfizer and six international cancer research groups, announced the launch of PATINA – a randomized, open-label, Phase 3 clinical study of the cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor palboci

Previous page 1 2 Next page